Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tri-Ad5 Vaccine in Advanced Cancer
NCT03384316Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Gene Editing, Viral Vector Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ETBX-011, ETBX-061 and ETBX-051 in cancer, solid tumor, prostate cancer (PCa) and 3 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Serious and Non-serious Adverse Events at 16 months and Recommended Phase 2 Dose at 3 weeks. Started Jan 2018; status: completed.
02
Drugs
ETBX-011ETBX-061ETBX-051
03
Conditions
cancersolid tumorprostate cancer (PCa)lung cancerbreast cancer
Beyond the preview
Go deeper on NCT03384316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384316.